For clinical data, Pai’s et al. found that in the “real world” practice in patients with hypertension and diabetes, those treated with ARBs regimen reduces 26% of stroke in contrast to the group with angiotensin converting enzyme inhibitors (ACEIs) regimen (Pai et al., 2016). Here, ACE is linked to diabetes mellitus.